WCN26-6572 ORIGIN 3: A PHASE 3 TRIAL OF ATACICEPT IN IgA NEPHROPATHY

IgA nephropathy, the most common primary glomerulopathy worldwide, is a disorder of B-cell origin with kidney pathology characterized by mesangial IgA-containing immune complex accumulation. At least 50% of patients progress to kidney failure or death within 10-20 years of diagnosis. Atacicept is a native human transmembrane activator, calcium-modulator and cyclophilin ligand interactor (TACI)-Fc fusion protein that inhibits two key immunoregulatory cytokines, B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), considered central to the pathophysiology of IgA nephropathy.